Answers are grounded in this paper and cite their sources.
1Dept. of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Germany 2German Liver Foundation, Germany 3German Center for Infection Research (DZIF); Partner Site Hannover-Braunschweig, Germany 4Center for Individualized Infection Medicine (CiiM), Hannover, Germany To be included: Pol et al. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study. Correspondence Markus Cornberg, Dept. of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Germany. Email: [email protected] Correspondence Heiner Wedemeyer, Dept. of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Germany. Email: [email protected]
No takes yet. Share an insight, caveat, or question.
Cornberg et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: